Literature DB >> 19571405

Oral administration of synthetic retinoid Am80 (Tamibarotene) decreases brain beta-amyloid peptides in APP23 mice.

Kohichi Kawahara1, Kentaro Nishi, Michita Suenobu, Hideyuki Ohtsuka, Akira Maeda, Kenichiro Nagatomo, Akihiko Kuniyasu, Matthias Staufenbiel, Madoka Nakagomi, Koichi Shudo, Hitoshi Nakayama.   

Abstract

The purpose of this study is to investigate whether a synthetic retinoid Am80 (tamibarotene) exhibits any improving effects on amyloid precursor protein (APP)23 mice, a model of Alzheimer's disease. Am80 was orally administered in feed to 20-week (5-month)-old APP23 mice at a dose of 0 (control) or 0.5 mg/kg/d for 14 weeks. The Am80 treatment reduced significantly the insoluble Abeta levels in brain, in particular Abeta(42), while it gave no apparent effects on the soluble Abeta levels. The results suggest that oral administration of Am80 may have potency to reduce the extracellular Abeta(42) of insoluble and possibly oligomeric or protofibril forms, which are related to the cause and/or progression of Alzheimer's disease. The Am80 treatment showed no significant effect on spatial learning and memory of APP23 mice by Morris water maze analysis. The main reason for the absence of significance seems based on the large deviation and some mice both in the treated and the non-treated groups would neither swim nor make efforts to reach the platform.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19571405     DOI: 10.1248/bpb.32.1307

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  14 in total

Review 1.  Regulation of α-secretase ADAM10 expression and activity.

Authors:  Kristina Endres; Falk Fahrenholz
Journal:  Exp Brain Res       Date:  2011-10-04       Impact factor: 1.972

Review 2.  Retinoic acid signaling pathways in development and diseases.

Authors:  Bhaskar C Das; Pritam Thapa; Radha Karki; Sasmita Das; Sweta Mahapatra; Ting-Chun Liu; Ingrid Torregroza; Darren P Wallace; Suman Kambhampati; Peter Van Veldhuizen; Amit Verma; Swapan K Ray; Todd Evans
Journal:  Bioorg Med Chem       Date:  2013-11-22       Impact factor: 3.641

Review 3.  Molecular Anti-inflammatory Mechanisms of Retinoids and Carotenoids in Alzheimer's Disease: a Review of Current Evidence.

Authors:  Niyaz Mohammadzadeh Honarvar; Ahmad Saedisomeolia; Mina Abdolahi; Amir Shayeganrad; Gholamreza Taheri Sangsari; Babak Hassanzadeh Rad; Gerald Muench
Journal:  J Mol Neurosci       Date:  2016-11-18       Impact factor: 3.444

Review 4.  Drug repositioning for Alzheimer's disease.

Authors:  Anne Corbett; James Pickett; Alistair Burns; Jonathan Corcoran; Stephen B Dunnett; Paul Edison; Jim J Hagan; Clive Holmes; Emma Jones; Cornelius Katona; Ian Kearns; Patrick Kehoe; Amrit Mudher; Anthony Passmore; Nicola Shepherd; Frank Walsh; Clive Ballard
Journal:  Nat Rev Drug Discov       Date:  2012-11       Impact factor: 84.694

Review 5.  Harnessing endophenotypes and network medicine for Alzheimer's drug repurposing.

Authors:  Jiansong Fang; Andrew A Pieper; Ruth Nussinov; Garam Lee; Lynn Bekris; James B Leverenz; Jeffrey Cummings; Feixiong Cheng
Journal:  Med Res Rev       Date:  2020-07-13       Impact factor: 12.944

6.  Nuclear Receptors as Therapeutic Targets for Neurodegenerative Diseases: Lost in Translation.

Authors:  Miguel Moutinho; Juan F Codocedo; Shweta S Puntambekar; Gary E Landreth
Journal:  Annu Rev Pharmacol Toxicol       Date:  2018-09-12       Impact factor: 13.820

7.  Enhanced lithium-induced brain recovery following cranial irradiation is not impeded by inflammation.

Authors:  Jordane Malaterre; Cameron S McPherson; Delphine Denoyer; Emily Lai; Jim Hagekyriakou; Sally Lightowler; Koishi Shudo; Matthias Ernst; David M Ashley; Jennifer L Short; Greg Wheeler; Robert G Ramsay
Journal:  Stem Cells Transl Med       Date:  2012-05-30       Impact factor: 6.940

8.  Identification of disulfiram as a secretase-modulating compound with beneficial effects on Alzheimer's disease hallmarks.

Authors:  Sven Reinhardt; Nicolai Stoye; Mathias Luderer; Falk Kiefer; Ulrich Schmitt; Klaus Lieb; Kristina Endres
Journal:  Sci Rep       Date:  2018-01-22       Impact factor: 4.379

9.  Potential repurposing of oncology drugs for the treatment of Alzheimer's disease.

Authors:  Wataru Araki
Journal:  BMC Med       Date:  2013-03-26       Impact factor: 8.775

10.  Drug repositioning: an opportunity to develop novel treatments for Alzheimer's disease.

Authors:  Anne Corbett; Gareth Williams; Clive Ballard
Journal:  Pharmaceuticals (Basel)       Date:  2013-10-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.